Method of manufacturing CAF®09 liposomes affects immune responses induced by adjuvanted subunit proteins

Thakur, Aneesh; Wadhwa, Abishek; Lokras, Abhijeet; Müllertz, Olivia Amanda Oest; Christensen, Dennis; Franzyk, Henrik; Foged, Camilla

doi:10.1016/j.ejpb.2023.04.005

European Journal of Pharmaceutics and Biopharmaceutics

2023

DOI: 10.1016/j.ejpb.2023.04.005

|View full text |Cite

Method of manufacturing CAF®09 liposomes affects immune responses induced by adjuvanted subunit proteins

Aneesh Thakur

Abishek Wadhwa

Abhijeet Lokras

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants

Weth,

Dangerfield,

Timmer

et al. 2024

Vaccines

View full text Add to dashboard Cite

The Macrophage-inducible C-type lectin (Mincle) is a pattern-recognition receptor (PRR), which has shown much promise as a molecular target for the development of TH1/TH17-skewing vaccine adjuvants. In 2009, the first non-proteinaceous Mincle ligands, trehalose dimycolate (TDM) and trehalose dibehenate (TDB), were identified. This prompted a search for other Mincle agonists and the exploration of Mincle agonists as vaccine adjuvants for both preventative and therapeutic (anti-cancer) vaccines. In this review, we discuss those classes of Mincle agonists that have been explored for their adjuvant potential. These Mincle agonists have been used as stand-alone adjuvants or in combination with other pathogen-associated molecular patterns (PAMPs) or immunomodulatory agents. We will also highlight recently identified Mincle ligands with hitherto unknown adjuvanticity. Conjugate vaccines that contain covalently linked adjuvants and/or adjuvant–antigen combinations are also presented, as well as the different formulations (e.g., oil-in-water emulsions, liposomes, and particulate delivery systems) that have been used for the codelivery of antigens and adjuvants. Insofar the reader is presented with a thorough review of the potential of Mincle-mediated vaccine adjuvants, including historical context, present-day research and clinical trials, and outstanding research questions, such as the role of ligand presentation and Mincle clustering, which, if better understood, will aid in the development of the much-needed TH1/TH17-skewing vaccine adjuvants.

show abstract

Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants

Weth,

Dangerfield,

Timmer

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Method of manufacturing CAF®09 liposomes affects immune responses induced by adjuvanted subunit proteins

Cited by 1 publication

References 65 publications

Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants

Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants

Contact Info

Product

Resources

About